Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial-Reference-Cited by-同舟云学术

Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial

Published:2024-01 Issue:1 Volume:6 Page:e40-e50
ISSN:2665-9913
Container-title:The Lancet Rheumatology
language:en
Short-container-title:The Lancet Rheumatology

Author:

Leng Xiaomei,Leszczyński Piotr,Jeka Sławomir,Liu Sheng-Yun,Liu Huaxiang,Miakisz Małgorzata,Gu Jieruo,Kilasonia Lali,Stanislavchuk Mykola,Yang Xiaolei,Zhou Yinbo,Dong Qingfeng,Rezk Mourad,Mitroiu Marian,Addison Janet,Zeng Xiaofeng

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference10 articles.

1. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases;Kay;Ann Rheum Dis,2018

2. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems;Kvien;Semin Arthritis Rheum,2022

3. A phase I clinical study comparing the tolerance, immunogenicity, and pharmacokinetics of proposed biosimilar BAT1806 and reference tocilizumab in healthy Chinese men;Zhang;Front Pharmacol,2021

4. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study;Jones;Ann Rheum Dis,2010

5. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial;Smolen;Lancet,2008

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48);Arthritis Research & Therapy;2024-09-07

2. Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab;BioDrugs;2024-06-18

3. Non-TNF biologics and their biosimilars in rheumatoid arthritis;Expert Opinion on Biological Therapy;2024-05-22

4. Correction to Lancet Rheumatol 2024; 6: e40–50;The Lancet Rheumatology;2024-03

5. Biosimilar tocilizumab—better access and lower cost?;The Lancet Rheumatology;2024-01